Contrasting of Sierra Oncology Inc. (SRRA) and Aytu BioScience Inc. (NASDAQ:AYTU)

Since Sierra Oncology Inc. (NASDAQ:SRRA) and Aytu BioScience Inc. (NASDAQ:AYTU) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of both companies.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sierra Oncology Inc. N/A 0.00 54.84M -0.76 0.00
Aytu BioScience Inc. 6.53M 4.62 12.05M -7.14 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of Sierra Oncology Inc. and Aytu BioScience Inc.


Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Sierra Oncology Inc. 0.00% -43.8% -40.2%
Aytu BioScience Inc. -184.53% -73.8% -39.6%

Risk & Volatility

Sierra Oncology Inc. is 67.00% more volatile than Standard & Poor’s 500 due to its 1.67 beta. Competitively, Aytu BioScience Inc. is 367.00% more volatile than Standard & Poor’s 500, because of the 4.67 beta.


Sierra Oncology Inc. has a Current Ratio of 10.8 and a Quick Ratio of 10.8. Competitively, Aytu BioScience Inc.’s Current Ratio is 4.7 and has 4.4 Quick Ratio. Sierra Oncology Inc.’s better ability to pay short and long-term obligations than Aytu BioScience Inc.

Insider & Institutional Ownership

Sierra Oncology Inc. and Aytu BioScience Inc. has shares held by institutional investors as follows: 66.7% and 40.1%. Insiders held 0.1% of Sierra Oncology Inc. shares. Comparatively, insiders own roughly 2.7% of Aytu BioScience Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sierra Oncology Inc. 6.25% 9.29% -0.65% -7.83% -35.44% 15.91%
Aytu BioScience Inc. -10.34% 5.06% 85.71% 122.17% -73.6% 162.49%

For the past year Sierra Oncology Inc.’s stock price has smaller growth than Aytu BioScience Inc.


Aytu BioScience Inc. beats on 5 of the 9 factors Sierra Oncology Inc.

Sierra Oncology, Inc., a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer. It also engages in developing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase that is in preclinical development stage. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; and ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative measurement of static oxidation reduction potential in human semen. Further, the company provides Fiera personal care device, a hands-free wearable product for women that is designed to enhance interest in and physical readiness for sex. Aytu BioScience, Inc. is based in Englewood, Colorado.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.